A First-in-Human, Phase I Trial of MK-6598, an Inhibitor of the Immune Checkpoint IL4I1, With or Without Pembrolizumab for Advanced Solid Tumors
Authors:
- Markus JoergerMarkus Joerger
- Nicolas MachNMNicolas Mach
- Rahima JamalRJRahima Jamal
- Anastasios StathisASAnastasios Stathis
- Steven F. PowellSPSteven F. Powell
- Dagmar HessDHDagmar Hess
- Andrey LobodaALAndrey Loboda
- Michael LassmanMLMichael Lassman
- Carolina CabralCCCarolina Cabral
- Chiara C. KemalCKChiara C. Kemal
- Yao ChenYCYao Chen
- Yunlong YangYYYunlong Yang
Open Access
- 29 October 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications